If someone find a webcast of this presentation with the new pre-clinical data, please post it.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
July 17, 2007--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that it presented data from pre-clinical and Phase 1a studies at the 6th Annual Metabolic Diseases Drug Discovery and Development World Summit in San Diego, California on July 17, 2007. As previously announced, Jill Milne, Ph.D., Senior Director of Biology at Sirtris, delivered a keynote address "SIRT1 Activation: A Novel Mechanism for Treating Type 2 Diabetes."
Dr. Milne presented data which showed that SRT501, Sirtris' proprietary formulation of resveratrol, reduces glucose and improves insulin sensitivity in multiple pre-clinical models of Type 2 Diabetes. Dr. Milne also presented pharmacokinetic (PK) data from a Phase 1a study conducted by Sirtris in which healthy volunteers who were dosed with SRT501 had an improved exposure as compared with other published studies. Both the area under the curve concentrations (AUC) as well as the maximal concentrations (Cmax) were shown to be improved with SRT501 as compared with literature values for resveratrol. SRT501 is currently being tested in a Phase 1b study in patients with Type 2 Diabetes.
Furthermore, Dr. Milne presented data with certain Sirtris proprietary novel chemical SIRT1 activators, structurally unrelated to resveratrol, which were shown to reduce glucose, improve insulin sensitivity, improve glucose tolerance, and increase the number and function of mitochondria in multiple pre-clinical models of Type 2 Diabetes. In addition, studies in a pre-clinical model demonstrate improved insulin sensitivity in muscle, liver, and fat cells.
"Sirtris scientists continue to make significant progress in the development of SIRT1 activators for diseases of aging such as Type 2 Diabetes. Indeed, the new data presented today further extend Sirtris' scientific leadership in advancing sirtuin modulators as a new class of innovative therapeutics," said Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris.
